The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•31 March 2026•

1 min read

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion; APLS Shares Surge 140%

Key Facts

1Biogen announced an agreement to acquire Apellis Pharmaceuticals in a deal valued at $5.6 billion.

2Apellis Pharmaceuticals (APLS) shares surged 140% in pre-market trading following the deal announcement.

3The acquisition aims to enhance Biogen's rare-disease treatment portfolio and accelerate its expansion into nephrology.

Create Free Account

Version History

1 additional source confirmed this story

Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals in a landmark deal valued at approximately $5.6 billion. Following the announcement, shares of Apellis Pharmaceuticals (APLS) skyrocketed by 140% in pre-market trading as investors reacted to the premium valuation. This strategic acquisition is designed to significantly bolster Biogen's existing portfolio of rare-disease treatments. Furthermore, the deal is expected to accelerate Biogen's expansion into the high-growth field of nephrology. By integrating Apellis's innovative pipeline, Biogen aims to diversify its revenue streams and strengthen its long-term drug development strategy. This move underscores a major consolidation trend within the biotechnology sector as large players seek to acquire specialized clinical assets to drive future growth.